Coya Therapeutics, Inc. 8K

Coya Therapeutics reported first quarter 2026 results and a corporate update featuring regulatory milestones for COYA 302, a broadened ALS trial protocol, an $11.1 million private placement, and a net loss of $7.2 million on cash of $50.7 million.

On May 12, 2026, Coya Therapeutics, Inc. reported its financial results for the quarter ended March 31, 2026 and provided a corporate update, highlighting FDA Fast Track designation for COYA 302 in ALS, FDA acceptance of an IND for COYA 302 in frontotemporal dementia, amendments to the ALSTARS Phase 2 trial protocol to broaden patient eligibility and accelerate enrollment, and an $11.1 million private placement led by Dr. Reddy’s Laboratories and Greenlight Capital, alongside disclosure of a quarterly net loss of $7.2 million, cash and equivalents of $50.7 million, and increased G&A expenses driven largely by a non-cash stock option modification related to the resignation of the former Executive Chairman.

Filing Facts

CIK

1835022

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-218198

Alert Tier

7